16/06/22 -"Our target price is cut on account of a drop in both intrinsic valuations (DCF and NAV) as well as the relative valuations, which now factor in the multiple near-term headwinds (supply chain ..."
Pages
59
Language
English
Published on
16/06/22
You may also be interested by these reports :
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...
07/01/26
Yesterday, Meta announced a delay in the international rollout of the Ray-Ban display smart glasses. The market reacted positively to this news, on ...
30/12/25
Despite revising our estimates and target price downward, DiaSorin remains a compelling investment opportunity. This is underpinned by strong ...
15/12/25
We have revised our estimates upwards to account for enhanced profitability, despite the effects of tariffs and foreign exchange headwinds. This ...